Samsara BioCapital, LLC
•CIK: 1744967•Filing: Q4 2025
**Samsara BioCapital, LLC** manages $969M across a concentrated portfolio of 21 holdings, demonstrating a deep focus within the biotechnology sector. The fund's top conviction positions include SRRK at $303.8M and MLYS at $213.1M, representing significant capital allocation to key growth areas. Further substantial exposure is maintained in KLRS ($109.3M) and SEPN ($87.8M). This structure indicates a highly selective, high-conviction approach to early-stage and innovative life science assets.
Total AUM
$969.3M
QoQ Performance
+26.6%
Positions
21
Top 10 Concentration
91.6%
Latest Filing
Q4 2025
Top Holdings Allocation
SRRK
MLYS
KLRS
SEPN
ALMS
SRRK31.3%
MLYS22.0%
KLRS11.3%
SEPN9.1%
ALMS5.8%
NGNE3.6%
IVA2.5%
GOSS2.3%
📈 Biggest Buys
📉 Biggest Sells
Sector Breakdown
Other100.0%
🚪 Exited Positionssold since Q3 2025
—
AVADEL PHARMACEUTICALS PLC
SOLD
$10.3M
+5 more exited positions
Changes from Q3 2025
NEW4 new positions
↑5 increased
↓8 decreased
Historical Filings
Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023